2024, Vol. 4, Issue 1, Part A
Novel RP-HPLC method for the simultaneous estimation of candesartan and hydrochlorothiazide in bulk and tablet formulation
Author(s): Ravi Shankar Sahu, Shailesh Pradhan, Chandrakant Sahu, Ramsheela, Nikhil Rathor and Mukesh Patel
Abstract: No single publication was found while scanning the common international databases for literature on any analytical RP-HPLC approach for the routine simultaneous determination of candesartan (CDS) and hydrochlorothiazide (HCT) combinations in a pharmaceutical tablet formulation. A straightforward, robust, accurate, cost-effective, and easy solution was developed to solve the issue. Establishing a validated RP-HPLC approach for CDS and HCT estimation in bulk and tablet formulation is the aim of this work. The method was created using a 250 mm × 4 mm 5 μm Qualisil-5 BDS C8 column. ACN and water were used to make up the mobile phase, which was provided at a flow rate of 1.0 mL/min and detected at a wavelength of 272 nm. The experiment was run at room temperature with an injection volume of 10 μL. The retention times of OFL (internal standard), CDS, and HCT were 2.146 min, 2.548 min, and 3.883 min, respectively. Linearity, accuracy, precision, and robustness—the four validation criteria were all found to be within acceptable bounds. For both CDS and HCT, the calibration plots were produced between 5 and 60 μg/mL, with r2 values of 0.998 in each case. With an RSD of <2, the recovery of CDS and HCT was determined to be 99.8% and 99.1%, respectively. The regular analysis of CDS and HCT in bulk as well as in tablet dosage form may be carried out using this RP-HPLC technique, which has been proven to be quick, specific, exact, and accurate. With less analytical time and a perfectly defined peak, the separation was complete.
Pages: 44-49 | Views: 140 | Downloads: 75Download Full Article: Click Here
How to cite this article:
Ravi Shankar Sahu, Shailesh Pradhan, Chandrakant Sahu, Ramsheela, Nikhil Rathor, Mukesh Patel. Novel RP-HPLC method for the simultaneous estimation of candesartan and hydrochlorothiazide in bulk and tablet formulation. Int J Pharm Sci Drug Anal 2024;4(1):44-49.